Novozymes Statistics

Total Valuation

Novozymes has a market cap or net worth of 34.05 billion. The enterprise value is 35.70 billion.

Market Cap	34.05B
Enterprise Value	35.70B

Important Dates

The last earnings date was Thursday, May 8, 2025.

Earnings Date	May 8, 2025
Ex-Dividend Date	Apr 7, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-8.56%
Shares Change (QoQ)	+68.44%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	346.42M

Valuation Ratios

The trailing PE ratio is 68.71 and the forward PE ratio is 30.82.

PE Ratio	68.71
Forward PE	30.82
PS Ratio	7.76
PB Ratio	2.81
P/TBV Ratio	23.28
P/FCF Ratio	51.51
P/OCF Ratio	33.17
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 26.61, with an EV/FCF ratio of 54.01.

EV / Earnings	72.04
EV / Sales	7.72
EV / EBITDA	26.61
EV / EBIT	34.15
EV / FCF	54.01

Financial Position

The company has a current ratio of 1.66, with a Debt / Equity ratio of 0.15.

Current Ratio	1.66
Quick Ratio	1.03
Debt / Equity	0.15
Debt / EBITDA	1.44
Debt / FCF	2.78
Interest Coverage	11.41

Financial Efficiency

Return on equity (ROE) is 6.97% and return on invested capital (ROIC) is 7.25%.

Return on Equity (ROE)	6.97%
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	7.25%
Return on Capital Employed (ROCE)	6.64%
Revenue Per Employee	414,444
Profits Per Employee	46,831
Employee Count	10,582
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +16.97% in the last 52 weeks. The beta is 0.55, so Novozymes's price volatility has been lower than the market average.

Beta (5Y)	0.55
52-Week Price Change	+16.97%
50-Day Moving Average	64.51
200-Day Moving Average	62.23
Relative Strength Index (RSI)	65.00
Average Volume (20 Days)	57,108

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Novozymes had revenue of 4.39 billion and earned 495.57 million in profits. Earnings per share was 1.71.

Revenue	4.39B
Gross Profit	2.31B
Operating Income	996.22M
Pretax Income	664.50M
Net Income	495.57M
EBITDA	1.28B
EBIT	996.22M
Earnings Per Share (EPS)	1.71

Full Income Statement

Balance Sheet

The company has 269.67 million in cash and 1.84 billion in debt, giving a net cash position of -1.57 billion.

Cash & Cash Equivalents	269.67M
Total Debt	1.84B
Net Cash	-1.57B
Net Cash Per Share	n/a
Equity (Book Value)	12.14B
Book Value Per Share	26.04
Working Capital	838.41M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.03 billion and capital expenditures -365.54 million, giving a free cash flow of 661.05 million.

Operating Cash Flow	1.03B
Capital Expenditures	-365.54M
Free Cash Flow	661.05M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 52.73%, with operating and profit margins of 22.72% and 11.30%.

Gross Margin	52.73%
Operating Margin	22.72%
Pretax Margin	15.15%
Profit Margin	11.30%
EBITDA Margin	29.12%
EBIT Margin	22.72%
FCF Margin	15.07%

Dividends & Yields

This stock pays an annual dividend of 0.54, which amounts to a dividend yield of 0.76%.

Dividend Per Share	0.54
Dividend Yield	0.76%
Dividend Growth (YoY)	-4.48%
Years of Dividend Growth	n/a
Payout Ratio	54.46%
Buyback Yield	8.56%
Shareholder Yield	9.32%
Earnings Yield	1.46%
FCF Yield	1.94%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on December 9, 2011. It was a forward split with a ratio of 5.

Last Split Date	Dec 9, 2011
Split Type	Forward
Split Ratio	5

Scores

Novozymes has an Altman Z-Score of 5.71.

Altman Z-Score	5.71
Piotroski F-Score	n/a